For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

Leo Pharma’s inaccurate Innohep app has prompted a slap-down from the PMCPA. The U.K. | Leo Pharma’s inaccurate Innohep app ...

Leo is smaller than the big pharma giants (revenue last year was €1.83bn at mid-week exchange rates, and earnings before interest, tax, depreciation and amortisation (ebitda) was €180m) and so ...

SIPTU members in pharmaceutical manufacturer Leo Pharma in Dublin have commenced industrial action in a dispute over redundancies. The row centres on the company's decision to make five workers ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal ...

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE). Just a few months after buying Timber Pharma, LEO ...

“LEO’s expertise and global footprint make it the best choice to advance and achieve the full potential of Timber Pharmaceuticals’ portfolio of product candidates. We believe that LEO has the ...

LEO Pharma has entered into a definitive agreement to acquire US biopharma company Timber Pharmaceuticals in a deal worth up to $36m. The transaction will give LEO access to Timber’s lead ...

Leo Pharma has taken a leading approach in the trial transparency debate by pledging to open the past 23 years of drug data by 2017. The dermatology specialist announced it would make clinical study ...